Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Question: Medical Chart Review of an Infliximab Infusion

From the College  |  Issue: June 2018  |  June 21, 2018

A 73-year-old female established patient with rheuma­toid arthritis affecting multiple joints and with positive rheumatoid factor returns to the office for an infliximab infusion.

She denies any fevers, cough, dyspnea or concurrent illness. She has joint pain of 6 on the pain scale. She is on an NSAID, weekly methotrexate subcutaneous injections, folic acid and ranitidine. No changes were made in the patient’s medications. The patient weighs 130 lbs., and her past family and social history has not changed since it was taken six months ago.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

She was administered 50 mg of diphenhydramine intravenously over two minutes as a prophylactic measure against a drug reaction to the infliximab. Her IV started at 10:00 a.m., and the intravenous infliximab 300 mg was infused from 10:15 a.m. until 12:28 p.m.

How should this encounter be coded?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Click here for the answer(s).

Share: 

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & Codinginfliximab

Related Articles

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Rheumatology Coding Corner Answer: Medical Chart Review of an Infliximab Infusion

    June 21, 2018

    Take the challenge. CPT codes: 96413, 96415, 96375, J1745x30, J1200x1 ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEDiagnosis ICD-10: M05.79 With the total infusion time of two hours and 13 minutes, CPT code 96413 is used to code for the first hour of the infusion and 96415 for the additional hour. The infusion would have to be 31…

    Rheumatology Coding Corner Question: Physical Examination with Infliximab Infusion

    July 14, 2016

    A 12-year-old male established patient with inflammatory bowel disease with associated juvenile spondyloarthropathy returns to the office for a follow-up visit for his infliximab infusion. The patient reports moderate pain in his right hip after walking for extended periods of time or after sports activities. He denies any other joint pain and denies any joint…

    Reading Rheum

    July 1, 2007

    Handpicked Reviews of Contemporary Literature

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences